Literature DB >> 25227725

The frequency and the effects of 21-hydroxylase gene defects in congenital adrenal hyperplasia patients.

Deniz Kirac1, Ahmet Ilter Guney2, Teoman Akcay3, Tulay Guran4, Korkut Ulucan5, Serap Turan4, Deniz Ergec2, Gulsah Koc2, Fatih Eren6, Elif Cigdem Kaspar7, Abdullah Bereket4.   

Abstract

Congenital adrenal hyperplasia (CAH) is a group of genetic endocrine disorders, caused by enzyme deficiencies in the conversion of cholesterol to cortisol. More than 90% of the cases have 21-hydroxylase deficiency (21-OHD). The clinical phenotype of the disease is classified as classic, the severe form, and nonclassic, the mild form. In this study, it was planned to characterize the mutations that cause 21-OHD in Turkish CAH patients by direct sequencing and multiplex ligation-dependent probe amplification (MLPA) analysis and to investigate the type of CAH (classic or nonclassic type) that these mutations cause. A total of 124 CAH patients with 21-OHD and 100 healthy volunteers were recruited to the study. Most of the mutations were detected by direct sequencing. Large gene deletions/duplications/conversions were investigated with MLPA analysis. Results were evaluated statistically. At the end of our study, 66 different variations were detected including SNPs and deletions/duplications/conversions. Of these variations, 18 are novel, of which three cause amino acid substitutions. In addition, 15 SNPs which cause amino acid changes were identified among these variations. If similar results are obtained in different populations, these mutations, in particular the novel mutation 711 G>A, may be used as markers for prenatal diagnosis.
© 2014 John Wiley & Sons Ltd/University College London.

Entities:  

Keywords:  21‐OHD; CAH; CYP21A2; MLPA analysis; direct sequencing

Mesh:

Substances:

Year:  2014        PMID: 25227725     DOI: 10.1111/ahg.12083

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  4 in total

1.  Development of CYP21A2 Genotyping Assay for the Diagnosis of Congenital Adrenal Hyperplasia.

Authors:  Mayara Jorgens Prado; Simone Martins de Castro; Cristiane Kopacek; Maricilda Palandi de Mello; Thaiane Rispoli; Tarciana Grandi; Cláudia Maria Dornelles da Silva; Maria Lucia Rosa Rossetti
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

2.  New Horizons: Molecular Basis and Novel Therapeutics in Congenital Adrenal Hyperplasia.

Authors:  Rajendra Prasad; Sonia Deswal
Journal:  Indian J Clin Biochem       Date:  2022-01-17

3.  Structure-based activity prediction of CYP21A2 stability variants: A survey of available gene variations.

Authors:  Carlos D Bruque; Marisol Delea; Cecilia S Fernández; Juan V Orza; Melisa Taboas; Noemí Buzzalino; Lucía D Espeche; Andrea Solari; Verónica Luccerini; Liliana Alba; Alejandro D Nadra; Liliana Dain
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379

4.  The spectrum of CYP21A2 gene mutations in patients with classic salt wasting form of 2l-hydroxylase deficiency in a Chinese cohort.

Authors:  Yang Liu; Jie Zheng; Nan Liu; Xiaowei Xu; Xinjie Zhang; Ying Zhang; Guoxu Li; Geli Liu; Chunquan Cai; Jianbo Shu
Journal:  Mol Genet Genomic Med       Date:  2020-09-21       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.